Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
07 May 2019Website:
http://www.trevitherapeutics.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 01 Nov 2024 23:41:02 GMTDividend
Analysts recommendations
Institutional Ownership
TRVI Latest News
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn. , Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025.
Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) chronic cough reaches 50% enrollment milestone; sample size re-estimation results expected in December 2024 Human Abuse Potential (HAP) study dosing complete; topline results expected in December 2024 NEW HAVEN, Conn. , Oct. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today provided updates on its clinical development programs.
NEW HAVEN, Conn. , Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V.
Professor Alyn Morice will present an analysis of cough relief in patients with idiopathic pulmonary fibrosis who were treated with nalbuphine ER NEW HAVEN, Conn. , Sept. 26, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at CHEST 2024 held in Boston, Massachusetts from October 6-9.
Publicly traded biopharmaceutical firms can have large, sometimes triple-bagger, expectations placed on them by Wall Street analysts. This is especially true for companies like Trevi Therapeutics NASDAQ: TRVI, which don't yet have any products approved by the Food and Drug Administration (FDA).
Professor Jacky Smith will present on the correlation between the change in objective cough count and improvement in patient-reported outcomes with nalbuphine ER in IPF patients NEW HAVEN, Conn. , Sept. 4, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that data from the Phase 2a CANAL trial will be presented at the European Respiratory Society (ERS) Congress 2024 being held in Vienna, Austria from September 7-11.
NEW HAVEN, Conn. , Aug. 28, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in September.
Trevi Therapeutics, Inc. (NASDAQ:TRVI ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Jennifer Good - President and CEO Lisa Delfini - Chief Financial Officer David Clark - Chief Medical Officer Conference Call Participants Thomas Smith - Leerink Partners Leland Gershell - Oppenheimer Mayank Mamtani - B. Riley Securities Brandon Folkes - Rodman & Renshaw John Gionco - Needham & Company Debanjana Chatterjee - JonesTrading Operator Good afternoon.
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
What type of business is Trevi Therapeutics?
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
What sector is Trevi Therapeutics in?
Trevi Therapeutics is in the Healthcare sector
What industry is Trevi Therapeutics in?
Trevi Therapeutics is in the Biotechnology industry
What country is Trevi Therapeutics from?
Trevi Therapeutics is headquartered in United States
When did Trevi Therapeutics go public?
Trevi Therapeutics initial public offering (IPO) was on 07 May 2019
What is Trevi Therapeutics website?
https://www.trevitherapeutics.com
Is Trevi Therapeutics in the S&P 500?
No, Trevi Therapeutics is not included in the S&P 500 index
Is Trevi Therapeutics in the NASDAQ 100?
No, Trevi Therapeutics is not included in the NASDAQ 100 index
Is Trevi Therapeutics in the Dow Jones?
No, Trevi Therapeutics is not included in the Dow Jones index
When was Trevi Therapeutics the previous earnings report?
No data
When does Trevi Therapeutics earnings report?
The next expected earnings date for Trevi Therapeutics is 08 November 2024